MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Search

Grifols SA

Open

SectorFinanciën

8.466 0.38

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.42

Max

8.564

Belangrijke statistieken

By Trading Economics

Inkomsten

17M

69M

Verkoop

183M

2B

K/W

Sectorgemiddelde

36.313

20.525

EPS

0.101

Winstmarge

3.491

Werknemers

23,833

EBITDA

57M

482M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+65.92% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.6B

5.2B

Vorige openingsprijs

8.09

Vorige sluitingsprijs

8.466

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Grifols SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2025, 17:19 UTC

Acquisities, Fusies, Overnames

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 apr 2025, 13:02 UTC

Acquisities, Fusies, Overnames

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 apr 2025, 10:13 UTC

Acquisities, Fusies, Overnames

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 jul 2024, 10:40 UTC

Acquisities, Fusies, Overnames

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 jul 2024, 09:13 UTC

Acquisities, Fusies, Overnames

Grifols Faces Delisting Bid From Founding Family and Brookfield

15 apr 2025, 09:55 UTC

Marktinformatie

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Peer Vergelijking

Prijswijziging

Grifols SA Prognose

Koersdoel

By TipRanks

65.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14.02 EUR  65.92%

Hoogste 19.05 EUR

Laagste 11 EUR

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Grifols SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technische score

By Trading Central

8.006 / 8.544Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.